Detalhe da pesquisa
1.
Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease.
Nat Immunol
; 22(2): 128-139, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33398182
2.
An evaluation of the trimmed mean approach in clinical trials with dropout.
Pharm Stat
; 17(3): 278-289, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29624854
3.
Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study.
Eur Heart J
; 37(17): 1360-9, 2016 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26757788
4.
Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome.
Eur Heart J
; 36(43): 3020-2, 2015 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26112886
5.
CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome.
Br J Clin Pharmacol
; 80(6): 1388-98, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26264702
6.
The Association between Factor XI Deficiency and the Risk of Bleeding, Cardiovascular, and Venous Thromboembolic Events.
Thromb Haemost
; 122(5): 808-817, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34555861
7.
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
JAMA
; 306(19): 2099-109, 2011 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-22089718
8.
Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.
Arterioscler Thromb Vasc Biol
; 29(1): 140-6, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18988892
9.
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
JAMA
; 297(12): 1362-73, 2007 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-17384435
10.
Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects.
Pharmacotherapy
; 36(7): 749-56, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27284735
11.
Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients.
J Clin Lipidol
; 10(3): 519-527.e4, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27206939
12.
Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.
J Am Coll Cardiol
; 66(20): 2201-2210, 2015 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26564598
13.
Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors.
Pharmacol Res Perspect
; 3(5): e00179, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26516590
14.
Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults.
J Pharm Pharmacol
; 66(11): 1576-85, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24961753
15.
Sample size reestimation by Bayesian prediction.
Biom J
; 49(3): 365-77, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17623342
16.
Bayesian predictive approach to interim monitoring in clinical trials.
Stat Med
; 25(13): 2178-95, 2006 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16007570